Form 4: Dare Bioscience Director, Robin Joan Steele, Acquires 40,000 Stock Options

Director Robin Joan Steele acquired 40,000 stock options in Dare Bioscience, Inc. on June 5, 2024.

Summary

• On June 5, 2024, Robin Joan Steele, a director of Dare Bioscience, Inc., acquired 40,000 stock options.
• The exercise price of these options is $0.43.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The options become fully exercisable upon a change in control of the issuer.
• Following the transaction, Steele beneficially owns 40,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this event alone doesn't strongly indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting and exercisability of the options are contingent upon continued service as a director and a potential change in control of the issuer.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates